• Je něco špatně v tomto záznamu ?

Ideal marker for targeted axillary dissection (IMTAD): a prospective multicentre trial

J. Žatecký, O. Coufal, O. Zapletal, O. Kubala, M. Kepičová, A. Faridová, K. Rauš, J. Gatěk, P. Kosáč, M. Peteja

. 2023 ; 21 (1) : 252. [pub] 20230819

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu multicentrická studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016541

BACKGROUND: Targeted axillary dissection (TAD) is an established method for axillary staging in patients with breast cancer after neoadjuvant chemotherapy (NAC). TAD consists of sentinel lymph node biopsy and initially pathological lymph node excision, which must be marked by a reliable marker before NAC. METHODS: The IMTAD study is a prospective multicentre trial comparing three localisation markers for lymph node localisation (clip + iodine seed, magnetic seed, carbon suspension) facilitating subsequent surgical excision in the form of TAD. The primary outcome was to prospectively compare the reliability, accuracy, and safety according to complication rate during marker implantation and detection and marker dislodgement. RESULTS: One hundred eighty-nine patients were included in the study-in 135 patients clip + iodine seed was used, in 30 patients magnetic seed and in 24 patients carbon suspension. The complication rate during the marker implantation and detection were not statistically significant between individual markers (p = 0.263; p = 0.117). Marker dislodgement was reported in 4 patients with clip + iodine seed localisation (3.0%), dislodgement did not occur in other localisation methods (p = 0.999). The false-negativity of sentinel lymph node (SLN) was observed in 8 patients, the false-negativity of targeted lymph nodes (TLN) wasn ́t observed at all, the false-negativity rate (FNR) from the subcohort of ypN + patients for SLN is 9.6% and for TLN 0.0%. CONCLUSION: The IMTAD study indicated, that clip + iodine seed, magnetic seed and carbon suspension are statistically comparable in terms of complications during marker implantation and detection and marker dislodgement proving their safety, accuracy, and reliability in TAD. The study confirmed, that the FNR of the TLN was lower than the FNR of the SLN proving that the TLN is a better marker for axillary lymph node status after NAC. TRIAL REGISTRATION: NCT04580251. Name of registry: Clinicaltrials.gov. Date of registration: 8.10.2020.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016541
003      
CZ-PrNML
005      
20231026105734.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12957-023-03147-x $2 doi
035    __
$a (PubMed)37596658
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Žatecký, Jan $u Department of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. janzatecky.jz@gmail.com $u Department of Surgery, Silesian Hospital in Opava, Opava, Czech Republic. janzatecky.jz@gmail.com $u Faculty of Public Policies, The Institute of Paramedical Health Studies, Silesian University, Opava, Czech Republic. janzatecky.jz@gmail.com $1 https://orcid.org/0000000204150853
245    10
$a Ideal marker for targeted axillary dissection (IMTAD): a prospective multicentre trial / $c J. Žatecký, O. Coufal, O. Zapletal, O. Kubala, M. Kepičová, A. Faridová, K. Rauš, J. Gatěk, P. Kosáč, M. Peteja
520    9_
$a BACKGROUND: Targeted axillary dissection (TAD) is an established method for axillary staging in patients with breast cancer after neoadjuvant chemotherapy (NAC). TAD consists of sentinel lymph node biopsy and initially pathological lymph node excision, which must be marked by a reliable marker before NAC. METHODS: The IMTAD study is a prospective multicentre trial comparing three localisation markers for lymph node localisation (clip + iodine seed, magnetic seed, carbon suspension) facilitating subsequent surgical excision in the form of TAD. The primary outcome was to prospectively compare the reliability, accuracy, and safety according to complication rate during marker implantation and detection and marker dislodgement. RESULTS: One hundred eighty-nine patients were included in the study-in 135 patients clip + iodine seed was used, in 30 patients magnetic seed and in 24 patients carbon suspension. The complication rate during the marker implantation and detection were not statistically significant between individual markers (p = 0.263; p = 0.117). Marker dislodgement was reported in 4 patients with clip + iodine seed localisation (3.0%), dislodgement did not occur in other localisation methods (p = 0.999). The false-negativity of sentinel lymph node (SLN) was observed in 8 patients, the false-negativity of targeted lymph nodes (TLN) wasn ́t observed at all, the false-negativity rate (FNR) from the subcohort of ypN + patients for SLN is 9.6% and for TLN 0.0%. CONCLUSION: The IMTAD study indicated, that clip + iodine seed, magnetic seed and carbon suspension are statistically comparable in terms of complications during marker implantation and detection and marker dislodgement proving their safety, accuracy, and reliability in TAD. The study confirmed, that the FNR of the TLN was lower than the FNR of the SLN proving that the TLN is a better marker for axillary lymph node status after NAC. TRIAL REGISTRATION: NCT04580251. Name of registry: Clinicaltrials.gov. Date of registration: 8.10.2020.
650    _2
$a lidé $7 D006801
650    _2
$a prospektivní studie $7 D011446
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a lymfadenektomie $7 D008197
650    _2
$a biopsie sentinelové lymfatické uzliny $7 D021701
650    12
$a lymfadenopatie $7 D000072281
650    _2
$a uhlík $7 D002244
650    12
$a jod $7 D007455
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
700    1_
$a Coufal, Oldřich $u Department of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Surgical Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Zapletal, Ondřej $u Department of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Surgical Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kubala, Otakar $u Department of Surgical Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Department of Surgery, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Kepičová, Markéta $u Department of Surgery, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Faridová, Adéla $u Oncogynecology Centre, The Institute for the Care of Mother and Child, Prague, Czech Republic
700    1_
$a Rauš, Karel $u Oncogynecology Centre, The Institute for the Care of Mother and Child, Prague, Czech Republic
700    1_
$a Gatěk, Jiří $u Department of Surgery, EUC Clinic Zlín, Zlín, Czech Republic $u Tomáš Baťa University in Zlín, Zlín, Czech Republic
700    1_
$a Kosáč, Peter $u Department of Surgery, EUC Clinic Zlín, Zlín, Czech Republic
700    1_
$a Peteja, Matúš $u Department of Surgery, Silesian Hospital in Opava, Opava, Czech Republic $u Faculty of Public Policies, The Institute of Paramedical Health Studies, Silesian University, Opava, Czech Republic
773    0_
$w MED00008253 $t World journal of surgical oncology $x 1477-7819 $g Roč. 21, č. 1 (2023), s. 252
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37596658 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105729 $b ABA008
999    __
$a ok $b bmc $g 2000200 $s 1202903
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 21 $c 1 $d 252 $e 20230819 $i 1477-7819 $m World journal of surgical oncology $n World J Surg Oncol $x MED00008253
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Možnosti archivace